步长制药全资子公司获磷酸奥司他韦胶囊药品注册证书

Core Viewpoint - The announcement by the company indicates the approval of a new drug, Oseltamivir Phosphate Capsules, for the treatment and prevention of influenza, which could enhance its product portfolio and market position in the pharmaceutical industry [1] Group 1: Company Developments - The company, through its wholly-owned subsidiary Shaanxi Buchang High-tech Pharmaceutical Co., Ltd., has received the drug registration certificate from the National Medical Products Administration for Oseltamivir Phosphate Capsules [1] - The approved drug is indicated for the treatment of influenza A and B in adults and children aged 1 year and older, as well as for the prevention of influenza A and B in adults and adolescents aged 13 years and older [1]